Supplementary Fig.S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Key Points
Key points are not available for this paper at this time.
Abstract
Antibody-dependent cell-mediated cytotoxicity of MW282 mAb, 9MW2821, and enfortumab vedotin (EV) measured by a cell-based reporter-gene assay.
AI에게 질문
Like
Bookmark
Share
AI에게 질문
Like
Bookmark
Share
Supplementary Fig.S8 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers | Synapse